Hot Paths

Lilly’s Zepbound shows promise in teen obesity trial (LLY:NYSE)

Overweight boy with young female doctor in white coat

ljubaphoto/E+ via Getty Images

Eli Lilly’s (LLY) Zepbound helped adolescents with obesity or excess weight and related health conditions achieve substantial weight reductions in a new study, supporting the company’s push to expand the medicine’s use to younger patients.

The 160 participants, whose average starting

Exit mobile version